Woodbine, MD, June 5, 2020–Rithim Biologics®, Inc. is honored to be presenting at and attending the 2020 BIO International Convention Digital within the NIH Innovation Zone, June 8-12. Rithim’s co-Founders, Dr. Kevin Donahue and Ronald Anderson, will be presenting a 15-minute presentation on the company’s current efforts in delivering gene therapy to the heart. Initial product development targets the prevention of atrial fibrillation in a post-operative setting (POAF). POAF is an estimated $3 B burden on US healthcare and greater than $7 B on the world’s healthcare. Current products in development include the TheraKit™ inclusive of the cardiac gene therapy and either the SafeBrush™ for open heart applications or the DAAViS™ catheter system for less invasive cardiac surgical procedures.
News
